Durvalumab for stage III non-small cell lung cancer (NSCLC): early access programme (EAP) in University Hospitals Birmingham (UHB), UK. (January 2020) - Powell, R.; Kussaibati, R.; Page, E.; Wingate, E.; Khan, A.; Stevenson, R.; Ghafoor, Q.; Baijal, S.